LÃ¡szlÃ³ MarÃ³di

List of Publications by Year
in descending order

39 papers	3,001 citations	471509 17 h-index	315739 38 g-index
39 all docs	39 docs citations	39 times ranked	4104 citing authors

#	Article	IF	Citations
1	Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2011, 208, 1635-1648.	8.5	739
2	Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. Journal of Experimental Medicine, 2010, 207, 291-297.	8.5	663
3	Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood, 2016, 127, 3154-3164.	1.4	465
4	Innate cellular immune responses in newborns. Clinical Immunology, 2006, 118, 137-144.	3.2	206
5	Neonatal Innate Immunity to Infectious Agents. Infection and Immunity, 2006, 74, 1999-2006.	2.2	143
6	New and recurrent gain-of-functionSTAT1mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. Journal of Medical Genetics, 2013, 50, 567-578.	3.2	105
7	Pathogenic Fungi Regulate Immunity by Inducing Neutrophilic Myeloid-Derived Suppressor Cells. Cell Host and Microbe, 2015, 17, 507-514.	11.0	99
8	Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options â€“ a Retrospective Analysis. Journal of Clinical Immunology, 2015, 35, 538-549.	3.8	73
9	Phenotypic characteristics of the p.Asn215Ser (p.N215S) G<scp>LA</scp> mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Molecular Genetics & Genomic Medicine, 2018, 6, 492-503.	1.2	70
10	Herpes in STAT1 gain-of-function mutation. Lancet, The, 2012, 379, 2500.	13.7	66
11	Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms. Current Opinion in Pediatrics, 2007, 19, 693-697.	2.0	55
12	Primary immunodeficiency diseases: the J Project. Lancet, The, 2009, 373, 2179-2181.	13.7	34
13	Consensus Middle East and North Africa Registry on Inborn Errors of Immunity. Journal of Clinical Immunology, 2021, 41, 1339-1351.	3.8	33
14	Recurrent infection with genetically identical pneumococcal isolates in a patient with interleukin-1 receptor-associated kinase-4 deficiency. Journal of Medical Microbiology, 2007, 56, 863-865.	1.8	26
15	Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. Journal of Allergy and Clinical Immunology, 2010, 126, 910-917.	2.9	21
16	The creation and progress of the J Project in Eastern and Central Europe. Annals of the New York Academy of Sciences, 2011, 1238, 65-73.	3.8	21
17	Characterization of a new disease-causing mutation ofSH2D1Ain a family with X-linked lymphoproliferative disease. Human Mutation, 2005, 25, 506-506.	2.5	18
18	The Evolving View of IL-17-Mediated Immunity in Defense Against Mucocutaneous Candidiasis in Humans. International Reviews of Immunology, 2015, 34, 348-363.	3.3	17

#	Article	IF	Citations
19	Fifteen Years of the J Project. Journal of Clinical Immunology, 2019, 39, 363-369.	3.8	16
20	The Spread of the J Project. Journal of Clinical Immunology, 2013, 33, 1037-1042.	3.8	15
21	Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome. Journal of Clinical Immunology, 2015, 35, 681-688.	3.8	14
22	A novel IL2RG mutation associated with maternal T lymphocyte engraftment in a patient with severe combined immunodeficiency. Journal of Human Genetics, 2006, 51, 495-497.	2.3	13
23	Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel STAT1 Gain-of-Function Mutation. Frontiers in Immunology, 2020, 11, 967.	4.8	12
24	Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains. Journal of Medical Microbiology, 2012, 61, 198-203.	1.8	11
25	Inherited TOP2B Mutation: Possible Confirmation of Mutational Hotspots in the TOPRIM Domain. Journal of Clinical Immunology, 2021, 41, 817-819.	3.8	8
26	Editorial: Advances in Primary Immunodeficiency in Central-Eastern Europe. Frontiers in Immunology, 2021, 12, 667727.	4.8	8
27	Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy, 2019, 11, 397-406.	2.0	7
28	The J Daughter Siberia Project. Journal of Clinical Immunology, 2021, 41, 262-265.	3.8	6
29	Novel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype. Clinical and Experimental Immunology, 2021, 205, 354-362.	2.6	6
30	Inborn errors of T cell immunity underlying autoimmune diseases. Expert Review of Clinical Immunology, 2017, 13, 97-99.	3.0	5
31	The Konya Declaration for Patients with Primary Immunodeficiencies. Journal of Clinical Immunology, 2020, 40, 770-773.	3.8	5
32	A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the JÂProject. Pediatric Allergy and Immunology, 2022, 33, .	2.6	5
33	A novel large deletion and single nucleotide insertion in the Wiskottâ€“Aldrich syndrome protein gene. European Journal of Haematology, 2015, 95, 93-98.	2.2	4
34	A Rose Amongst the Thorns: the Mission of the J Project in a Conflictual World. Journal of Clinical Immunology, 2022, 42, 1151-1155.	3.8	4
35	The 10th anniversary of the world primary immunodeficiency week: A J Project celebration. European Journal of Immunology, 2021, 51, 2364-2366.	2.9	3
36	Hematopoietic Stem Cell Gene Therapy For Wiskott- Aldrich Syndrome. Blood, 2013, 122, 718-718.	1.4	2

#	Article	IF	Citations
37	Persistently Increased Anti-cytokine Antibodies Without Clinical Disease in a Boy with APS1 Genotype. Journal of Clinical Immunology, 2022, 42, 433-436.	3.8	2
38	From IgnÃ¡c Semmelweis to Primary Immunodeficiencies: a Bicentenary Commemoration. Journal of Clinical Immunology, 2018, 38, 247-250.	3.8	1
39	Peculiar hyper-IgM syndrome. Case report / Sindrom hiper-IgM atipic. Prezentare de caz. Romanian Journal of Laboratory Medicine, 2015, 23, 341-345.	0.2	0